文献速递肝病

非选择性β受体阻滞剂在TIPS置入后无价值

No value of non-selective beta-blockers after TIPS-insertion.
PubMed 文献 · Aliment Pharmacol Ther · 2024-08-27

该回顾性研究纳入305例连续患者,评估TIPS置入时及出院后继续使用非选择性β受体阻滞剂(NSBB)对肝硬化并发症和生存的影响,另前瞻性纳入45例分析48种可溶性炎症标志物;结果显示NSBB治疗与全身炎症、肝功能失代偿及生存均无显著关联。

要点

  • TIPS置入时使用NSBB或出院后继续治疗均与肝功失代偿、肝硬化并发症或死亡风险降低无关。
  • 前瞻性队列中NSBB摄入与白细胞、C反应蛋白或任何可溶性炎症标志物水平降低或变化更显著无关。
  • 结论认为NSBB治疗及其后续继续或停用对全身炎症、肝功失代偿和生存似乎无显著影响。

核心结论

  • TIPS置入时使用NSBB及之后继续或停用似乎对全身炎症、肝功失代偿发生和生存无显著影响。

研究设计与样本

  • 回顾性研究纳入305例连续患者,采用多变量竞争风险分析。
  • 前瞻性队列纳入45例患者,分析基线及TIPS置入后3个月和6个月的48种可溶性炎症标志物。

主要发现

  • 总体175例(57.4%)患者在TIPS置入前接受NSBB治疗,出院时降至131例(22.9%),其中36例(27.5%)在1年随访内停用NSBB。
  • TIPS置入时NSBB治疗或出院后继续治疗均与肝功失代偿、个体肝硬化相关并发症或死亡风险降低无关,围手术期和随访期间均如此。
  • 前瞻性队列中NSBB摄入与白细胞、C反应蛋白或任何其他可溶性炎症标志物在任何 investigated 时间点的水平降低或更显著变化无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Non-selective beta-blockers (NSBB) are a well-established treatment in patients with clinically significant portal hypertension. However, their potential role after insertion of a transjugular intrahepatic portosystemic shunt (TIPS) still needs to be determined. Of note, recent studies suggested that favourable anti-inflammatory effects of NSBB might be independent from pressure reduction. This study aimed to evaluate whether NSBB-treatment is associated with amelioration of systemic inflammation (SI), hepatic decompensation and survival after TIPS-insertion. METHODS: In a retrospective study comprising 305 consecutive patients, we investigated the impact of NSBB-intake at TIPS-placement on periinterventional cirrhosis-associated complications and continued NSBB-treatment after discharge on complications including hepatic decompensation and mortality during 1-year follow-up, employing multivariable competing-risk-analyses. In a prospective cohort including 45 patients, we performed a comprehensive analysis of SI analysing 48 soluble inflammatory markers (SIMs) at baseline plus 3 and 6 months after TIPS-insertion. RESULTS: Overall, 175 (57.4%) patients received NSBB-therapy prior to TIPS-insertion; upon discharge, this decreased to 131 (22.9%), with 36 (27.5%) discontinuing NSBB within 1-year follow-up. Neither NSBB-therapy at TIPS-insertion nor treatment-continuation after discharge were associated with lower risks for hepatic decompensation, individual cirrhosis-associated complications or mortality neither in the periinterventional period nor during follow-up. Similarly, in the prospective cohort NSBB-intake was not linked to lower levels or a more prominent change of WBC, CRP or any other SIM at any of the investigated time points. CONCLUSION: NSBB-therapy at the time of TIPS-insertion and its (dis-)continuation afterwards seems to have no significant impact on SI, development of hepatic decompensation and survival.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tiede A, Stockhoff L, Rieland H, et al. No value of non-selective beta-blockers after TIPS-insertion. Aliment Pharmacol Ther. 2024. PMID: 39192553. doi:10.1111/apt.18204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。